Skip to main content
Clinical Trials/NCT00200109
NCT00200109
Completed
Phase 1

ONSTIM: Occipital Nerve Stimulation for the Treatment of Intractable Migraine.

MedtronicNeuro2 sites in 2 countries110 target enrollmentMay 2004

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Chronic Migraine Headache
Sponsor
MedtronicNeuro
Enrollment
110
Locations
2
Primary Endpoint
A primary endpoint is not identified for this feasibility study.
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache greater than 15 days per month.

Method: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responsers were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups.

Detailed Description

The therapy under investigation involves a Medtronic neurostimulation device which delivers electrical impulses via insulated lead wires placed under the skin near the occipital nerves at the base of the head.

Registry
clinicaltrials.gov
Start Date
May 2004
End Date
May 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Chronic Migraine Headache by International Headache Society (IHS) criteria
  • compliance with daily questionnaire
  • headache that has not responded to at least two classes of headache medications
  • stable headache medication regimen

Exclusion Criteria

  • previous surgical procedures to disrupt the nerves of the neck relating to the headache
  • subjects who may require MRI or Diathermy

Outcomes

Primary Outcomes

A primary endpoint is not identified for this feasibility study.

Time Frame: No primary endpoint

Secondary Outcomes

  • Secondary endpoints included: patient daily questionnaire, Migraine Disability Assessment (MIDAS), functional disability, SF-36, acute medication use and subject satisfaction surveys.(No secondary endpoint)

Study Sites (2)

Loading locations...

Similar Trials